alnylam pharmaceuticals inc american biopharmaceutical company focused discovery development commercialization rna interference rnai genetically defined diseases company founded headquartered cambridge forbes included company innovative growth companies company spinoff max planck institute biophysical alnylam founded scientists phillip sharp paul schimmel david bartel thomas tuschl phillip zamore investors christoph westphal john kennedy clarke john maraganore founding company named alnilam star orions belt spelling modified make firm merged german pharmaceutical company ribopharma ag newly formed company also received million funding privateequity february alnylam pharmaceuticals filed company raised million began trading alny nasdaq stock company partnered medtronic develop drugdevice combinations treat neurodegenerative biogen idec develop treatments progressive multifocal entered nonexclusive alliance hoffmannla roche alnylam received million exchange access technology also partnered ionis pharmaceuticals found company regulus therapeutics focused microrna company formed alliances cubist pharmaceuticals kyowa hakko kirin market drug targeted respiratory syncytial expanded previous collaboration medtronic include chdi foundation huntingtons disease focused partnered glaxosmithkline develop rnai technology enhancing vaccine company entered alliance monsanto develop biotech solutions farming industry developing natural molecules crop formed partnership sanofi genzyme develop treatment transthyretinmediated amyloidosis hereditary disease source needed february formed partnership medicines company develop drug treat genetic form high july phase trial alnylam demonstrated statistically significant reduction protein called transthyretin ttr demonstrated human efficacy intravenous subcutaneous modes sanofi genzyme acquired percent stake alnylam increased rights several companys drugs million separate transaction alnylam announced purchased merck cos sirna therapeutics million cash million company million revenue market cap company purchased land norton massachusetts build manufacturing october phase iii clinical trial companys lead product revusiran halted due increased deaths drug arm trial company said terminating development february alnylam appointed former sanofi ceo olivier brandicourt board announced maraganore would step ceo succeeded companys chief operating officer yvonne greenstreet january december alnylam submitted clinical trial authorisation cta application medicines healthcare products regulatory agency united kingdom initiate phase study alnapp investigational rnai therapeutic targeting amyloid precursor protein app treatment alzheimers disease cerebral amyloid december novartis announced us food drug administration fda approved leqvio inclisiran small interfering rna sirna therapy lower lowdensity lipoprotein cholesterol leqvio indicated united states adjunct diet maximally tolerated statin therapy treatment adults clinical atherosclerotic cardiovascular disease ascvd heterozygous familial hypercholesterolemia hefh require additional lowering ldlc effect leqvio cardiovascular morbidity mortality explored clinical trials currently underway novartis obtained global rights develop manufacture commercialize leqvio license collaboration agreement alnylam alnylam still earn money writes losses losses gaap operating loss alnylam around million late alnylam expects achieve net profits financially july roche partnered alnylam pharmaceuticals deal worth billion development hypertension alnylam pharmaceuticals potential various development stages genetic medicine cardiometabolic disease hepatic infectious disease late companys lead candidate phase iii studies patisiran treatment targeting transthyretin ttr treatment ttrmediated amyloidosis attr patients compromised nervous system condition familial amyloidotic polyneuropathy august commercial name onpattro patisiran received us regulatory approval treat polyneuropathy patients hereditary attr september fda raised doubts efficacy patisiran treating cardiomyopathy associated transthyretinmediated amyloidosis attrcm fdas cardiovascular renal drugs advisory committee meeting scheduled september although apollob study met key endpoints fda questioned clinical significance results particularly patients background therapy tafamidis fda seeking committees input clinical meaningfulness patient populations patisiran use potentially challenging pfizers tafamidis dominance attrcm treatment decision alnylams application expected october patisiran previously approved hereditary attr amyloidosis polyneuropathy becoming first rna interference therapeutic approved httpsenwikipediaorgwikialnylampharmaceuticals